Genfit Sa · EURONEXT:GNFT
Genfit Sa — Investor Presentation (September 2026)
15 slides from Genfit Sa's investor presentation, September 2026
Slide 1: Corporate presentation
Corporate presentation September 2026
Slide 2: Disclaimer
Disclaimer IMPORTANT NOTICE – YOU MUST READ THE FOLLOWING BEFORE CONTINUING. THIS PRESENTATION HAS BEEN PREPARED BY GENFIT AND IS FOR INFORMATION PURPOSES ONLY. CERTAIN OF THE INFORMATION CONTAINED HEREIN CONCERNING ECONOMIC TRENDS AND PERFORMANCE IS BASED UPON OR DERIVED FROM INFORMATION PROVIDED B
Slide 3: Corporate Highlights
Corporate Highlights French biopharmaceutical company Partnership with Ipsen Listed on EURONEXT “GNFT” ► PBC: Iqirvo® launched in 20241,2 ▪ Upfront of €120M 25+ years in liver diseases, taking ▪ 8% equity stake early assets to commercial stage1 ▪ Up to €360M milestones (€105.5M received, potential €
Slide 4: Elafibranor Solid Commercial Performance from Ipsen in PBC
1. Elafibranor Solid Commercial Performance from Ipsen in PBC Iqirvo® sales (global, quarterly) since commercial launch1 400 350 94.4 300 Cumulative milestone payments received to date2 Global sales (millions of euros) 250 78.8 €105.5M 200 Cumulative royalties received to date3 76.6 150 283,4 €34M 1
Slide 5: ELSPIRE Ph3 Results and Ipsen's Updated Iqirvo Peak Sales Guidance in PBC
ELSPIRE Ph3 Results and Ipsen’s Updated Iqirvo® Peak Sales Guidance in PBC July 13, 2026 Upgraded Iqirvo peak sales of €1bn in PBC Source: Ipsen public disclosures. Commercial information has been derived from publicly available information released by Ipsen. GENFIT has not independently verified su
Slide 6: Ongoing Phase 3 Trial by Ipsen in PSC
Ongoing Phase 3 Trial by Ipsen in PSC Source: Ipsen’s 2025 Full-Year Results In February 2026, Ipsen confirmed the initiation of the first and only global Phase 3 clinical trial, addressing a significant unmet medical need, as no approved therapies currently exist for this severe and progressive dis
Slide 7: GENFIT recognized early the need for a single, non-invasive blood-based solution
2. MASH GENFIT recognized early the need for a single, non-invasive blood-based solution serving all stakeholders across the MASH care pathway 25+ Years of Focus Everybody Needs a Scalable, on Liver Diseases Reliable Diagnostic Tool Partnerships with A shift to in-house The turning pharma programs p
Slide 8: Non-Invasive Diagnosis of At-Risk MASH Utilizing GENFIT's Technology
Non-Invasive Diagnosis of At-Risk MASH Utilizing GENFIT’s Technology Patient identification landscape Labcorp’s NASHnext LDT test available to millions of patients NASHnext® reimbursed by Medicare under the Clinical Adults expected to present Laboratory Fee Schedule, for patients who meet coverage r
Slide 9: The Journey: a Decade of Development
The Journey: a Decade of Development Over the years, GENFIT leveraged its scientific expertise, extensive expert network and unique Phase 2 and Phase 3 tissue and blood sample datasets to develop a differentiated non-invasive technology addressing critical diagnostic and monitoring gaps Validation T
Slide 10: Today the MASH Market Reaches an Inflection Point
Today the MASH Market Reaches an Inflection Point Why Now: bottleneck shifting from treatment availability to patient identification, disease stratification and long-term management Resmetirom Approval & Blockbuster Sales in Year One Imminent Entry of Additional Molecules, incl. GLP-1s The first app
Slide 11: GENFIT's Technology Recognized by Leading Consortia, Guidelines and Industry Sponsors
GENFIT’s Technology Recognized by Leading Consortia, Guidelines and Industry Sponsors LITMUS consortium (Europe) NIMBLE consortium (U.S.) Topline results from NIMBLE consortium, stage 1 (N=1073)2 MASH At-risk MASH F stage ≥2 AUROC (95% CI) p (vs ALT) AUROC (95% CI) p (vs ALT) AUROC (95% CI) p (vs FI
Slide 12: IVD Expected to Unlock a ~$1.5B Peak Annual Laboratory Market Opportunity
IVD Expected to Unlock a ~$1.5B Peak Annual Laboratory Market Opportunity1 Base Case volume assumptions across the patient testing NIS2+ Estimated Revenue to Partner Lab (LDT+IVD) High Base Low journey, from initial diagnosis to long-term monitoring ~1.5B $1 500 Diagnosis Monitoring $1 350 >1B 1.7M
Slide 13: Three Assets Entering Phase 2 by Year-End (1/3)
3. CLINICAL PIPELINE Three Assets Entering Phase 2 by Year-End (1/3) GNS561 Cholangiocarcinoma (CCA) Phase 2 initiation 2H26 #2 GNS561 (Autophagy inhibitor) #1 Anticancer Therapies By entering the lysosomes and inhibiting PPT1, GNS561 acts to Chemotherapeutic agents block late-stage autophagy, which
Slide 14: Three Assets Entering Phase 2 by Year-End (2/3)
3. CLINICAL PIPELINE Three Assets Entering Phase 2 by Year-End (2/3) Nangibotide Acute On-Chronic Liver Failure (ACLF) Phase 2 initiation 2H26 GENFIT Advances Nangibotide in Phase 2 Clinical Investigation in ACLF September 14 2026 • GENFIT's acquisition of nangibotide, a differentiated late-stage as
Slide 15: Three Assets Entering Phase 2 by Year-End (3/3)
3. CLINICAL PIPELINE Three Assets Entering Phase 2 by Year-End (3/3) Nitazoxanide (NTZ) Acute On-Chronic Liver Failure The safety profile observed in Phase 1 (ACLF) and the consistent biological activity evidenced in ex vivo assays represent a meaningful step in development. These Phase 2 initiation